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lowers plasma PTH levels in patients with secondary hyper-A calcimimetic agent lowers plasma parathyroid hormone lev-
parathyroidism caused by end-stage renal disease.els in patients with secondary hyperparathyroidism.
Background. The calcimimetic agent R-568 lowers plasma
parathyroid hormone (PTH) levels in hemodialysis patients
with mild secondary hyperparathyroidism, but its efficacy in Secondary hyperparathyroidism continues to be a clin-those with more severe secondary hyperparathyroidism has
ically significant problem in many patients with end-stagenot been studied.
renal disease [1–4]. Parathyroid hormone (PTH) levelsMethods. Twenty-one patients undergoing hemodialysis three
times per week with plasma PTH levels between 300 and 1200 in serum or plasma are markedly elevated, and there is
pg/mL were randomly assigned to 15 days of treatment with histologic evidence of secondary hyperparathyroidism
either 100 mg of R-568 (N 5 16) or placebo (N 5 5). Plasma on bone biopsy in nearly half of adult patients receivingPTH and blood ionized calcium levels were measured at inter-
regular hemodialysis [1, 2]. Although treatment withvals of up to 24 hours after oral doses on days 1, 2, 3, 5, 8, 11,
1,25-dihydroxyvitamin D3, or calcitriol, lowers PTH lev-12, and 15.
Results. Pretreatment PTH levels were 599 6 105 (mean 6 els in many of those with secondary hyperparathyroid-
SE) and 600 6 90 pg/mL in subjects given R-568 or placebo, ism, serum calcium and/or phosphorus concentrations
respectively, and values on the first day of treatment did not often rise, limiting the dose that can be given safely [5–7].
change in those given placebo. In contrast, PTH levels fell by
The administration of other vitamin D sterols such as66 6 5%, 78 6 3%, and 70 6 3% at one, two, and four hours,
19-nor-1,25-dihydroxyvitamin D2 or 1-a-hydroxyvitaminrespectively, after initial doses of R-568, remaining below pre-
treatment values for 24 hours. Blood ionized calcium levels D2 may reduce plasma PTH levels with only modest
also decreased after the first dose of R-568 but did not change increments in the serum levels of calcium and phospho-
in patients given placebo. Despite lower ionized calcium con- rus [8, 9], but persistently elevated calcium or phosphorus
centrations on both the second and third days of treatment, concentrations preclude their use in many patients. Aspredose PTH levels were 422 6 70 and 443 6 105 pg/mL,
such, there is considerable interest in the developmentrespectively, in patients given R-568, and values fell each day
of pharmacological compounds that can control excessby more than 50% two hours after drug administration. Predose
PTH levels declined progressively over the first nine days of PTH secretion without raising serum calcium and/or
treatment with R-568 and remained below pretreatment levels phosphorus levels in patients with renal secondary hy-
for the duration of study. Serum total and blood ionized calcium perparathyroidism.
concentrations decreased from pretreatment levels in patients
Calcimimetic agents are small organic compounds thatgiven R-568, whereas values were unchanged in those given
modify signal transduction by the calcium-sensing recep-placebo. Blood ionized calcium levels fell below 1.0 mmol/L
in 7 of 16 patients receiving R-568; five patients withdrew from tor (CaSR) in the membrane of parathyroid cells [10, 11].
study after developing symptoms of hypocalcemia, whereas These agents enhance activation of the CaSR by extracel-
three completed treatment after the dose of R-568 was reduced. lular calcium ions and diminish the amount of PTH re-
Conclusions. The calcimimetic R-568 rapidly and markedly
leased from the parathyroid glands across a wide range of
blood ionized calcium concentrations [12]. Serum PTH
levels fall within a few hours after oral administration,Key words: hemodialysis, R-568, end-stage renal disease, chronic renal
disease, parathyroid hormone. and serum calcium concentrations decline subsequently
[13, 14]. These features distinguish calcimimetic com-
Received for publication October 25, 1999
pounds from the vitamin D sterols, which lower serumand in revised form January 25, 2000
Accepted for publication February 10, 2000 PTH levels by reducing pre-pro-PTH gene transcription
over many hours or several days [15, 16] and by raisingÓ 2000 by the International Society of Nephrology
436
Goodman et al: R-568 lowers plasma PTH levels 437
serum calcium concentrations caused by enhanced intes- unless they were using effective contraceptive measures
or had previously been rendered sterile surgically. Pa-tinal calcium absorption [17, 18].
Single oral doses of the calcimimetic compound R-568 tients were ineligible for study if the serum levels of
hepatic transaminases or bilirubin were more than twicehave been shown to lower serum PTH levels in women
with primary hyperparathyroidism [13], and the adminis- the upper limit of normal or if they were using medica-
tions such as selective seratonin reuptake inhibitors, tri-tration of two consecutive daily doses consistently re-
duced serum PTH values in hemodialysis patients with cyclic antidepressants, or b-adrenergic blocking agents
that are metabolized extensively by the P450 pathway.mild secondary hyperparathyroidism [14]. Moreover, the
prolonged use of R-568 effectively controlled life-threat- Additional exclusion criteria included a history of sei-
zures, malignancy, hyperthyroidism, granulomatous dis-ening hypercalcemia in a single patient with parathyroid
carcinoma [19]. The current study was undertaken to eases that could cause hypercalcemia, myocardial in-
farction within the previous six months, and a correctedassess the safety and efficacy of repeated oral doses of
R-568 in reducing plasma PTH levels over a 15-day pe- QT interval (QTc) on electrocardiogram that exceeded
450 milliseconds.riod in patients with end-stage renal disease and moder-
ate to severe secondary hyperparathyroidism.
Study design
The study was a randomized, double-blind, placebo-
METHODS
controlled, multicenter trial designed to determine the
Study subjects safety, efficacy, and pharmacokinetics of repeated oral
doses of R-568 in patients with end-stage renal diseaseMedically stable subjects 18 years of age or older,
undergoing hemodialysis three times per week for at undergoing hemodialysis three times per week. The in-
vestigational protocol comprised a 21-day interval duringleast three months, with biochemical evidence of second-
ary hyperparathyroidism, as judged by serum PTH levels which patients were screened for eligibility to participate
in the trial, a 15-day treatment period during which pa-between 300 and 1200 pg/mL, were considered to be
potential study candidates. Additional eligibility criteria tients were given single daily oral doses of 100 mg of
R-568 or placebo, and a post-treatment monitoring pe-included serum calcium levels above 9.0 mg/dL, serum
phosphorus levels above 3.0 mg/dL, serum aluminum riod of nine days. Participants continued to undergo reg-
ular hemodialysis three times per week throughout thelevels below 40 mg/L, serum CO2 levels above 15 mEq/L,
and serum potassium concentrations below 6.2 mEq/L. study using previously established individualized treat-
ment regimens. All dialysis parameters, including theTo limit the adverse effect of obtaining multiple blood
samples on the anemia of chronic renal failure, study concentration of calcium in dialysate, remained un-
changed during the study. Four of 16 patients given R-participants were required to have hematocrit values
above 30%, serum ferritin levels greater than 100 ng/mL, 568 were maintained on dialysate containing 3.5 mEq/L
of calcium, whereas 12 patients receiving R-568 and alland transferrin saturation values above 20%. Thres-
hold levels for hemodialysis adequacy were required for placebo-treated patients were managed using a dialysate
calcium level of 2.5 mEq/L. Doses of R-568 were givenall study subjects, as judged by urea reduction ratios
(URRs) of 65% or greater and/or measured Kt/V values 30 to 60 minutes after completing hemodialysis on the
days of regularly scheduled dialysis procedures and atexceeding 1.2.
Because R-568 undergoes hepatic metabolism by the the same time of the day on other study days.
Fifty-eight patients were screened as candidates forcytochrome P450 pathway, DNA was harvested from
peripheral blood white cells from all study candidates the study. Five patients were excluded because they me-
tabolized R-568 slowly, but none were excluded on theduring screening procedures, and genotyping was done
using the polymerase chain reaction (PCR) to identify basis of genotyping studies. Twenty-one patients quali-
fied for study, and they were randomly assigned to treat-selected alleles of the P450 CYP2D6 gene that account
for reduced cytochrome P450 activity. Patients who ment with either R-568 (N 5 16) or placebo (N 5 5)
using a predetermined ratio of 3:1. In one placebo-might have metabolized R-568 slowly based on the re-
sults of genotyping studies were excluded from further treated patient, plasma PTH levels both before and after
hemodialysis on the first day of treatment were less thanevaluation. In addition, candidates for the study were
given a single oral test dose of 100 mg of R-568, and 50 pg/mL, and they remained below 100 pg/mL for the
first eight days of study. Because these values consis-samples of blood were obtained 90 and 120 minutes later
for measurements of serum drug concentrations. Patients tently fell below the threshold PTH level of 300 pg/mL
required for entry into the study, the results from thiswhose serum R-568 levels exceeded 17 ng/mL in either
sample were considered to have low rates of drug elimi- patient were excluded from the final data analysis. The
study protocol was reviewed and approved by the Institu-nation, and they were excluded from study.
Women of childbearing age were excluded from study tional Review Board (IRB) at each study site, and writ-
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Table 1. Demographic data for study subjects giventen informed consent was obtained from each study par-
R-568 or placebo
ticipant.
R-568 PlaceboBaseline measurements of plasma PTH, total serum
(N 5 16) (N 5 4)calcium, and blood ionized calcium concentrations were
Age years 48.663.1 54.768.4obtained on the last two days of screening before the
[22–71] [37–76]
15-day treatment period. On the first day of treatment, Duration of renal disease years 10.962.0 11.961.9
[1–23] [2–23]blood samples were collected before hemodialysis for
Duration of dialysis years 6.761.0 8.361.7determinations of total serum calcium and plasma PTH
[1–13] [1–15]
concentrations. Blood ionized calcium levels were also Diabetes mellitus % 13 25
Calcitriol therapy % 38 50obtained on the first day of treatment both before and
Use of aluminum-containing 31 50after hemodialysis, prior to the administration of study
phosphate-binding agents %
drug. Predose plasma PTH levels were measured again Previous parathyroidectomy N 2 1
Gender M/F 13/3a 1/3on treatment days 2, 3, 5, 8, 10, 11, 12, and 15. Plasma
Race white/black/Hispanic 3/12/1b 3/1/0PTH and blood ionized calcium concentrations were
Dialysate calcium 3.5/2.5 mEq/L 4/12 0/4
measured at frequent intervals for up to 24 hours after
Values are mean 6 SE; results in brackets indicate range.the administration of R-568 or placebo on study days 1, ax2 5 6.43, P , 0.025
bx2 5 6.46, P , 0.052, 3, 5, 8, 10, 11, 12, and 15. Additional samples of blood
were obtained on days 5, 8, 11, and 15 for measurements
of drug concentrations in serum and to determine the
levels of total calcium and phosphorus in serum.
randomization procedures, the proportion of patients
randomized to receive R-568 who were men was higherBiochemical determinations
than in the placebo group. This was also the case for theSerum biochemical determinations were done by auto-
proportion of patients randomized to R-568 who weremated methods using a Vitro 750s analyzer as reported
black (Table 1).previously [13, 14]. Blood ionized calcium levels were
Baseline plasma PTH levels on the first day of treat-measured immediately after samples were collected us-
ment did not differ between patients given R-568 anding a calcium-sensitive electrode (Nova 8 CRT; Nova
those given placebo (Fig. 1). Plasma PTH levels de-Biomedical Corp., Waltham, MA, USA) [20]. Plasma
creased promptly in all subjects who received R-568,PTH levels were measured using a double antibody che-
whereas values remained unchanged in those given pla-miluminescent assay (DPC Immulite) [21].
cebo (Figs. 1 and 2). Plasma PTH concentrations during
the first day of treatment fell by 66 6 5%, 78 6 3%,Statistical analysis
and 70 6 3% at one, two, and four hours, respectively,All results are expressed as means 6 SE. Unpaired
after the administration of R-568. Although values roset-tests were used to compare mean values between the
from their nadir at two hours, PTH levels remained be-two groups [22]. Analysis of variance for repeated mea-
low pretreatment values 8 and 24 hours after initial dosessures was used to compare results for serial determina-
of R-568 (Fig. 1). There was no relationship betweentions with pretreatment, or baseline, values [22]. Cor-
the baseline plasma PTH level and either the percentagerelation analysis was completed using the least-squares
reduction in PTH one, two, or four hours after R-568method [22]. Chi-square analysis was done to compare
administration or the maximum reduction in plasmacategorical variables between groups [22]. For all statisti-
PTH values during the first 24 hours.cal tests, probability values of less than 5% were consid-
Blood ionized calcium levels fell after R-568 adminis-ered significant.
tration on the first day of treatment, whereas values did
not change in patients given placebo (Fig. 1). In contrast
RESULTS to the changes in plasma PTH, blood-ionized calcium
concentrations declined progressively throughout theThe mean age of patients treated with R-568 did not
day, and levels were persistently lower than predosediffer significantly from that of subjects given placebo,
values, even as PTH levels rose toward pretreatmentand the duration of renal disease prior to study also did
values four hours or more after initial doses of R-568not differ (Table 1). There were no significant differences
(Fig. 1). Blood-ionized calcium levels before dosing onbetween groups with respect to the duration of dialysis
the second day of treatment were substantially lowerbefore entering the study, the proportion of diabetics,
than baseline values 24 hours earlier (Fig. 1). There wasthe percentage of patients treated with calcitriol, the
no relationship, however, between the magnitude of theproportion of patients using aluminum hydroxide as a
fall in blood-ionized calcium after initial doses of R-568phosphate-binding agent, or the number who had under-
gone previous parathyroidectomy (Table 1). Despite and the pretreatment levels of either PTH or calcium.
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Fig. 1. Blood-ionized calcium (iCa21, A) and
plasma parathyroid hormone (PTH) levels
(B) during the first 24 hours after initial doses
of R-568 (d; N 5 16) or placebo (n; N 5 4).
Values represent mean 6 SE. *P , 0.05 vs.
hour 0 (baseline).
Fig. 2. Plasma PTH levels before and one
and two hours after initial doses of R-568 (d)
or placebo (n).
Blood-ionized calcium concentrations before the ad- substantially below the mean baseline PTH level of 5996
105 pg/mL before initial doses of R-568 (P , 0.05 forministration of R-568 were 1.13 6 0.02 and 1.23 6 0.03
mmol/L on the second and third days of study, respec- each; Table 2).
Although plasma PTH levels before dosing on thetively (Table 2); both values were lower than the mean
level of 1.31 6 0.02 mmol/L before dosing on the first second and third days of treatment had already de-
creased from pretreatment values, they fell an additionalday of treatment (P , 0.005 for each). Despite the reduc-
tions in blood-ionized calcium concentration, predose 50% within two hours after R-568 administration on
each of these two days (Table 2). The effect of R-568plasma PTH levels on the second and third days of study
were 422 6 70 and 443 6 105 pg/mL, respectively, values to lower plasma PTH levels was observed throughout
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Table 2. Plasma parathyroid hormone (PTH) and blood-ionized calcium levels on the second and third days of treatment with R-568
Day of treatment
Second Third
PTH Ionized calcium PTH Ionized calcium
Hours after dose pg/mL mmol/L pg/mL mmol/L
0 442670 1.1360.02 4436105 1.2360.03
2 211655a 208674a
[25468%] [25866%]
4 1.0960.02b 1.1060.04b
Values are mean 6 SE; the results in brackets indicate the percentage of change.
aP , 0.0001 vs. predose value
bP , 0.01 vs. predose value
Fig. 3. Plasma PTH levels before and two hours after doses of R-568 (d) or placebo (m) on days 5, 8, 11, and 15 of treatment. Blood ionized
calcium levels before and four hours after the administration of R-568 (s) or placebo (n) are also shown. Predose values were obtained after
hemodialysis but before drug administration on days 5, 8, and 15 and at the same time of day on day 11 when dialysis was not done. Values are
mean 6 SE. *P , 0.05 vs. predose value.
the 15-day treatment period; mean PTH values declined part, to the early withdrawal from study, based on proto-
col guidelines, of several patients who developed hypo-by at least 50% two hours after the oral administration
of R-568 on days 5, 8, 11, and 15 of treatment (Fig. 3). calcemia (vide infra; Fig. 4).
Blood ionized calcium concentrations decreased fol-In contrast to these findings, plasma PTH levels did not
change in patients given placebo (Fig. 3). Predose plasma lowing doses of R-568 on each day that repeated mea-
surements were obtained (Fig. 3 and Table 2). IonizedPTH levels declined progressively from pretreatment
values during the first nine days of R-568 administration, calcium levels declined two to four hours after drug ad-
ministration, and values remained below predose levelsand values were substantially lower throughout the 15-
day treatment period in patients given R-568 than in for as long as 24 hours. Accordingly, the levels of blood-
ionized calcium immediately before daily doses of R-568those receiving placebo (Fig. 4). The rise in mean serum
PTH values after the ninth day of treatment was due, in decreased progressively during treatment (Fig. 5). Total
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Fig. 4. Plasma PTH levels during 15 days of
treatment with R-568 (d) or placebo (n) and
during a nine-day post-treatment interval.
Blood samples were obtained after hemodial-
ysis but before drug administration on days
of regularly scheduled dialysis treatments.
Values are mean 6 SE. There was a significant
overall difference between patients treated
with R-568 and those given placebo. *P ,
0.05.
Fig. 5. Blood ionized calcium (A) and serum
total calcium concentrations (B) during 15
days of treatment with R-568 (d) or placebo
(n). Measurements were obtained approxi-
mately 20 hours after previous doses of R-568
or placebo but before beginning hemodialysis
on days corresponding to regularly scheduled
dialysis procedures. Values are mean 6 SE.
There was a significant overall difference be-
tween patients treated with R-568 and those
given placebo. *P , 0.05.
serum calcium concentrations also fell, and values in that repeated measurements were obtained. Accord-
ingly, values for the calcium-phosphorus ion product var-patients given R-568 were below baseline levels for much
of the 15-day treatment period (Fig. 5). Overall, serum ied primarily because of changes in total serum calcium
levels.total calcium levels were substantially lower in subjects
given R-568 than in those given placebo. Pharmacokinetic and pharmacodynamic data were
collected on days 8, 11, and 15 of treatment. Peak serumSerum phosphorus levels varied considerably from day
to day in both groups of subjects, but values did not levels of R-568 were achieved an average of 2.5 to 4.4
hours after daily oral doses, but there was considerablechange substantially from pretreatment levels during the
course of study in either group. In contrast to the changes heterogeneity among subjects (Table 3). Maximum drug
concentrations (Cmax) were observed as early as one hourin blood ionized calcium, serum phosphorus levels did
not decrease after doses of R-568 on the two study days and as late as 24 hours after individual doses of R-568.
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Table 3. Pharmacokinetic and pharmacodynamic data for subjects given R-568
Study day
1 8 11 15
N 15 12 11 9
Time to Cmax hours 3.360.8 2.860.5 2.560.7 4.460.5
[1.3–8.3] [0.8–6.4] [0.9–4.7] [1.0–24.4]
Maximum drug level (Cmax) ng/mL 4.860.8 5.261.1 7.761.1 4.861.3
[1.4–11.8] [0.4–20.7] [1.1–42.2] [1.3–10.9]
Area under curve (AUC) ng/ml/hr 36.664.9 41.669.3 40.3611.2 35.4610.2
[11.0–76.7] [0.7–127.8] [11.4–140.6] [6.0–109.6]
Values are mean 6 SE. Results in brackets indicate range.
Peak drug levels also varied widely among subjects, rang- during 15 days of treatment, and the percentage reduc-
tion in plasma PTH levels after individual doses wasing from 0.42 to 42.20 ng/mL. Mean values for Cmax dif-
fairly constant throughout the study, regardless of thefered by more than 50% among the four separate study
prevailing PTH level immediately before drug adminis-days (Table 3).
tration. Plasma PTH levels obtained before each dailyNone of the patients given placebo failed to complete
dose of R-568 declined progressively for the first ninethe 24-day study protocol. In contrast, 7 of 16 patients
days of treatment, and values remained below pretreat-treated with R-568 failed to complete the 15-day treat-
ment values for the duration of study despite substantialment period. Five patients withdrew after experiencing
reductions in both blood ionized and serum total calciumsymptoms that were consistent with hypocalcemia, in-
concentrations. The results indicate that calcimimeticcluding paresthesias and muscle weakness. None re-
compounds such as R-568 markedly diminish PTH secre-quired intravenous doses of calcium gluconate to manage
tion in patients with renal secondary hyperparathyroid-this consequence of therapy. Two patients were termi-
ism and that repeated doses of these agents achieve sus-nated from study according to protocol guidelines that
tained reductions in plasma PTH levels.mandated reductions in drug dosage if blood ionized
The current management of renal secondary hyper-calcium levels fell below 1.0 mmol/L and early study
parathyroidism relies largely on the use of vitamin Dtermination if ionized calcium values again reached lev-
sterols such as calcitriol, alfacalcidol, 19-nor-1,25-dihy-els below 1.0 mmol/L. Three patients successfully com-
droxyvitamin D2, or 1-a-hydroxyvitamin D2 to controlpleted 15 days of treatment after the dose of R-568 was
excess PTH secretion in patients undergoing regular dial-reduced to 50 mg daily because hypocalcemia developed.
ysis [4]. Each of these compounds reduces pre-pro-PTHNo study participant developed muscle twitching, muscle
gene transcription, making less hormone available forparalysis, or seizures.
release from the parathyroid glands. Several weeks orSeven of 16 subjects treated with R-568 developed
months of therapy are required, however, before plasmahypocalcemia, as defined by a blood ionized calcium level
PTH levels decline, particularly in patients with morebelow 1.0 mmol/L, whereas none of those given placebo
advanced secondary hyperparathyroidism [6, 7]; more-developed hypocalcemia. Gastrointestinal symptoms were
over, serum calcium and phosphorus levels often risemore common in subjects receiving R-568 than in those
during treatment [6, 7]. These biochemical changes limitgiven placebo, but these were generally described as mild
the doses of vitamin D sterols that can be given safely,and transient. Eight of 16 subjects given R-568 reported
and they often mandate reductions in dose or interrup-self-limited episodes of anorexia, nausea, or abdominal
tions in treatment. As a result, clinically significant reduc-cramping. None of these potential adverse effects were
tions in serum PTH levels cannot be achieved in manysevere enough to prompt withdrawal from study.
patients with secondary hyperparathyroidism, and high
serum calcium or phosphorus levels preclude the use of
DISCUSSION vitamin D sterols in others. In this context, the availabil-
These results demonstrate that daily oral doses of the ity of agents that reduce PTH secretion without further
calcimimetic compound R-568 rapidly and consistently raising serum calcium and phosphorus would be particu-
lower plasma PTH levels in hemodialysis patients with larly advantageous.
secondary hyperparathyroidism of varying severity. Plasma Previous studies indicate that single oral doses of
PTH levels decreased following single 100 mg doses in R-568 can lower serum PTH levels in women with pri-
all patients, reaching a mean nadir value more than 50% mary hyperparathyroidism [13], and similar responses
lower than predose levels after only two hours. The sup- were documented after two consecutive daily doses in
seven hemodialysis patients with mild secondary hyper-pressive effect of R-568 on PTH release was sustained
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parathyroidism [14]. In addition, Collins et al effectively NS). Since expression of the CaSR is reduced in parathy-
roid adenomas and in hyperplastic parathyroid tissuescontrolled life-threatening hypercalcemia for more than
two years using daily divided doses of R-568 in a patient removed from patients with advanced secondary hyper-
parathyroidism, as assessed by immunohistochemicalwith advanced parathyroid carcinoma [19]. Calcimimetic
agents have the capacity, therefore, to effectively control methods, proportionately smaller decreases in plasma
PTH levels after doses of R-568 might have been ex-excess PTH release in parathyroid disorders of widely
differing severity. pected in patients with the highest pretreatment PTH
values [25]. The absence such a relationship suggests isIn the current study, plasma PTH levels before treat-
ment ranged from 303 to 1130 pg/mL; 8 of 16 patients that reductions in CaSR expression in the parathyroid
glands may be confined to patients with very advancedgiven R-568 had values above 500 pg/mL, and 3 had
pretreatment PTH levels that exceeded 1000 pg/mL, val- secondary hyperparathyroidism, and the results of in
vivo assessments of parathyroid gland function in pa-ues generally considered to represent severe secondary
hyperparathyroidism in patients with end-stage renal dis- tients with end-stage renal disease are consistent with
this view [24]. Alternatively, decreases in CaSR expres-ease. The biochemical severity of secondary hyperpara-
thyroidism for participants in the current study did not sion may be more pronounced in parathyroid glands
with a nodular, rather than a diffuse, pattern of tissuediffer therefore from that described for subjects enrolled
in several recent clinical trials that examined the safety hyperplasia [26]. The number of subjects in the current
study was relatively small, however, and variations inand efficacy of two different vitamin D sterols in patients
undergoing regular hemodialysis [8, 9]. Despite the wide the pharmacokinetics and/or pharmacodynamics of
R-568 after oral administration could also account forrange of pretreatment serum PTH levels, values de-
creased in all subjects after initial doses of R-568, and the failure to document a relationship between the bio-
chemical severity of secondary hyperparathyroidism andserum PTH levels fell consistently within a few hours
after subsequent doses for the duration of study. This the PTH-suppressive effect of this particular calcimi-
metic agent.biochemical response persisted despite a progressive de-
cline in blood ionized and serum total calcium concentra- Seven of 16 patients treated with R-568 withdrew from
the study; 5 withdrew after experiencing symptoms oftions during the 15-day treatment interval. As such, the
daily administration of R-568 was sufficient to overcome hypocalcemia, whereas 2 others were withdrawn after
blood ionized calcium levels fell below 1.0 mmol/L morethe stimulatory effect of hypocalcemia on PTH release
in this group of patients with renal secondary hyperpara- than once. Three patients remained in the study after
the dose of R-568 was reduced because of transient hypo-thyroidism.
The percentage decrease in plasma PTH values two calcemia. Hypocalcemia potentially represents a major
consequence of therapy with calcimimetic agents, andhours after initial doses of R-568 varied from 52 to 92%.
Similar reductions in PTH values are seen in patients its occurrence in the current study was, at least in part,
caused by specifications of the protocol that precludedwith secondary hyperparathyroidism in whom maximum
suppression of PTH release is achieved by raising blood adjustments in the doses of oral calcium supplements
and vitamin D sterols, interventions that would counter-ionized calcium levels by approximately 0.2 mmol/L dur-
ing two-hour intravenous calcium infusions [23, 24]. Such act this drug-related effect, and the fixed starting dose
of 100 mg daily. Incremental upward titration from lowerfindings suggest that the administration of 100 mg oral
doses of R-568 is sufficient to activate fully the CaSR initial doses of calcimimetic agents might prove benefi-
cial. Considerable experience is needed to determineand to reduce PTH release from the parathyroid glands
to basal, or nonsuppressible, levels. Also, the percentage how these drugs can be used safely for long periods
without producing dose-limiting reductions in serumreduction in plasma PTH levels after R-568 administra-
tion did not differ between patients taking both R-568 calcium levels, and optimal calcimimetic dose titration
needs to be determined. In this regard, only one of sixand calcitriol versus those given R-568 alone. Thus, con-
current vitamin D therapy did not modify the acute effect patients receiving calcitriol together with R-568 in the
current study failed to complete the 15-day treatmentof R-568 to reduce plasma PTH levels in patients with
established secondary hyperparathyroidism. Patients with interval, and early termination on the second day of
R-568 therapy was not due to reductions in blood-ionizedincomplete suppression of excess PTH secretion during
treatment with vitamin D sterols may therefore benefit calcium. Thus, the coordinated use vitamin D sterols and
oral calcium supplements to offset the calcium-loweringfrom the addition of calcimimetic therapy.
Of interest, there was no relationship between the effect of calcimimetic agents warrants careful evaluation.
Such therapeutic combinations may prove to be effectivebiochemical severity of secondary hyperparathyroidism
in the current study, as judged by pretreatment, or base- in the clinical management of patients with moderate to
severe secondary hyperparathyroidism.line, PTH levels, and the magnitude of the decline in
plasma PTH after initial doses of R-568 (r 5 0.09, P 5 The mechanism responsible for the reductions in se-
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